142 related articles for article (PubMed ID: 11472877)
21. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
[TBL] [Abstract][Full Text] [Related]
22. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
[TBL] [Abstract][Full Text] [Related]
23. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
24. Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.
Bech S; Hjermind LE; Salvesen L; Nielsen JE; Heegaard NH; Jørgensen HL; Rosengren L; Blennow K; Zetterberg H; Winge K
Parkinsonism Relat Disord; 2012 Jan; 18(1):69-72. PubMed ID: 21873100
[TBL] [Abstract][Full Text] [Related]
25. Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
Marques TM; van Rumund A; Oeckl P; Kuiperij HB; Esselink RAJ; Bloem BR; Otto M; Verbeek MM
Neurology; 2019 Mar; 92(13):e1479-e1486. PubMed ID: 30814322
[TBL] [Abstract][Full Text] [Related]
26. Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism.
van Rumund A; Aerts MB; Esselink RAJ; Meijer FJA; Verbeek MM; Bloem BR
BMC Neurol; 2018 May; 18(1):69. PubMed ID: 29764386
[TBL] [Abstract][Full Text] [Related]
27. The discriminating properties of an optoelectronic movement analysis method in patients with parkinsonism.
Zackrisson T; Bergquist F; Eklund M; Holmberg B; Thorlin T
J Mot Behav; 2013; 45(5):415-22. PubMed ID: 23972026
[TBL] [Abstract][Full Text] [Related]
28. Acute challenge with apomorphine and levodopa in Parkinsonism.
Rossi P; Colosimo C; Moro E; Tonali P; Albanese A
Eur Neurol; 2000; 43(2):95-101. PubMed ID: 10686467
[TBL] [Abstract][Full Text] [Related]
29. Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders.
Zhu S; Bäckström D; Forsgren L; Trupp M
J Parkinsons Dis; 2022; 12(4):1169-1189. PubMed ID: 35253777
[TBL] [Abstract][Full Text] [Related]
30. Identification of candidate cerebrospinal fluid biomarkers in parkinsonism using quantitative proteomics.
Magdalinou NK; Noyce AJ; Pinto R; Lindstrom E; Holmén-Larsson J; Holtta M; Blennow K; Morris HR; Skillbäck T; Warner TT; Lees AJ; Pike I; Ward M; Zetterberg H; Gobom J
Parkinsonism Relat Disord; 2017 Apr; 37():65-71. PubMed ID: 28214264
[TBL] [Abstract][Full Text] [Related]
31. Pain processing in atypical Parkinsonisms and Parkinson disease: A comparative neurophysiological study.
Avenali M; Tassorelli C; De Icco R; Perrotta A; Serrao M; Fresia M; Pacchetti C; Sandrini G
Clin Neurophysiol; 2017 Oct; 128(10):1978-1984. PubMed ID: 28829981
[TBL] [Abstract][Full Text] [Related]
32. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
Williams DR; Lees AJ
Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379
[TBL] [Abstract][Full Text] [Related]
33. Transcranial sonography and [18F]fluorodeoxyglucose positron emission tomography for the differential diagnosis of parkinsonism: a head-to-head comparison.
Hellwig S; Reinhard M; Amtage F; Guschlbauer B; Buchert R; Tüscher O; Weiller C; Niesen WD; Meyer PT
Eur J Neurol; 2014 Jun; 21(6):860-6. PubMed ID: 24602186
[TBL] [Abstract][Full Text] [Related]
34. Measurements of transcallosally mediated cortical inhibition for differentiating parkinsonian syndromes.
Wolters A; Classen J; Kunesch E; Grossmann A; Benecke R
Mov Disord; 2004 May; 19(5):518-28. PubMed ID: 15133815
[TBL] [Abstract][Full Text] [Related]
35. [Regional cerebral blood flow single photon emission tomography (SPECT) and magnetic resonance imaging (MRI) may be useful in the diagnosis of patients with cortico-basal degeneration, progressive supranuclear palsy and multiple system atrophy].
Lass P; Sławek J; Derejko M; Dubaniewicz M
Neurol Neurochir Pol; 2003; 37 Suppl 5():263-74. PubMed ID: 15098354
[TBL] [Abstract][Full Text] [Related]
36. Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study.
Linder J; Stenlund H; Forsgren L
Mov Disord; 2010 Feb; 25(3):341-8. PubMed ID: 20108376
[TBL] [Abstract][Full Text] [Related]
37. A Card-type Odor Identification Test for Japanese Patients with Parkinson's Disease and Related Disorders.
Watanabe Y; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Uchiyama T; Kadowaki T; Matsubara T; Hirata K
Intern Med; 2017 Nov; 56(21):2871-2878. PubMed ID: 28943542
[TBL] [Abstract][Full Text] [Related]
38. Neurofilament Light Chain Levels in Frontotemporal Dementia and Progressive Supranuclear Palsy: A Systematic Review.
Bendstrup N; Hejl AM; Salvesen L
J Alzheimers Dis; 2022; 87(1):131-140. PubMed ID: 35275542
[TBL] [Abstract][Full Text] [Related]
39. Finger tapping analysis in patients with Parkinson's disease and atypical parkinsonism.
Djurić-Jovičić M; Petrović I; Ječmenica-Lukić M; Radovanović S; Dragašević-Mišković N; Belić M; Miler-Jerković V; Popović MB; Kostić VS
J Clin Neurosci; 2016 Aug; 30():49-55. PubMed ID: 27343040
[TBL] [Abstract][Full Text] [Related]
40. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes.
Stamelou M; Christ H; Reuss A; Oertel W; Höglinger G
Mov Disord; 2011 Apr; 26(5):901-5. PubMed ID: 21384428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
